2017-09-20T08:06:33-05:00 2016-12-31 043077056 MOODY FAMIGLIETTI & ANDRONICO LLP 1 HIGHWOOD DRIVE TEWKSBURY MA 01876 990 2016-01-01 463250612 EVIDENCE FOR HEALTHCARE IMPROVEMENT EVID 6175284013 TWO LIBERTY SQUARE NINTH FLOOR BOSTON MA 02109 SARAH EMOND CHIEF OPERATING OFFICER 6175284013 2017-09-18 1 MATTHEW KALIL CPA MBA P01517069 9785575300 66.152.247.30 2017-09-18 11:45:11 ED P 317E8747876FC67392754136350CB4FA072B998C 0EB5133F41FDFBE80A9C2996836CAFE7DD289EA1 2016 2021-01-29 14:40:06Z INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW STEVEN D PEARSON MD TWO LIBERTY SQUARE NINTH FLOOR BOSTON MA 02109 1408087 0 X ICER-REVIEW.ORG X 2013 CA ICER IS A TRUSTED NON-PROFIT ORGANIZATION THAT EVALUATES EVIDENCE ON THE VALUE OF MEDICAL TESTS, TREATMENTS AND DELIVERY SYSTEM INNOVATIONS AND MOVES THAT EVIDENCE INTO ACTION TO IMPROVE THE HEALTH CARE SYSTEM. TO ACCOMPLISH THIS GOAL ICER PERFORMS ANALYSES ON EFFECTIVENESS AND COSTS; DEVELOPS REPORTS USING INNOVATIVE METHODS THAT MAKE IT EASIER TO TRANSLATE EVIDENCE INTO DECISIONS; AND, MOST DISTINCTIVELY, FILLS A CRITICAL GAP BY CREATING SUSTAINABLE INITIATIVES WITH ALL HEALTH CARE STAKEHOLDERS THAT CAN ALIGN EFFORTS TO USE EVIDENCE TO DRIVE IMPROVEMENTS IN BOTH PRACTICE AND POLICY. THROUGH ALL ITS WORK, ICER SEEKS TO PLAY A PIVOTAL ROLE IN CREATING A FUTURE IN WHICH COLLABORATIVE EFFORTS TO MOVE EVIDENCE INTO ACTION PROVIDE A FOUNDATION FOR A MORE EFFECTIVE, EFFICIENT, AND JUST HEALTH CARE SYSTEM. 10 10 24 0 0 0 5481696 286234 965107 1120472 121 1381 0 0 6446924 1408087 0 0 0 0 1959472 2595566 0 0 19656 848728 1962495 2808200 4558061 3638724 -3149974 6739386 3862816 917553 1190957 5821833 2671859 X SUSTAINABLE ACCESS TO HIGH VALUE CARE FOR ALL PATIENTS. 0 0 1303280 THE CALIFORNIA TECHNOLOGY ASSESSMENT FORUM (CTAF), A CORE PROGRAM OF THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER), IS A NATIONALLY-RECOGNIZED COMMUNITY FORUM. CTAF CONVENES THREE TIMES EACH YEAR AT PUBLIC MEETINGS TO REVIEW OBJECTIVE EVIDENCE REPORTS AND DEVELOP RECOMMENDATIONS FOR HOW STAKEHOLDERS CAN APPLY EVIDENCE TO IMPROVE THE QUALITY AND VALUE OF HEALTH CARE.CTAF DIRECTLY ENGAGES CLINICIANS, PATIENTS, AND PAYERS DURING PUBLIC MEETINGS TO DISCUSS IMPLICATIONS OF THE EVIDENCE FOR CLINICAL DECISION-MAKING AND COVERAGE POLICIES. APPLICATION OF EVIDENCE TAKES SHAPE THROUGH NEW MEDICAL POLICIES, BENEFIT DESIGNS, AND PATIENT AND CLINICIAN TOOLS TO IMPROVE CLINICAL CARE AND PATIENT OUTCOMES. 881600 THE NEW ENGLAND COMPARATIVE EFFECTIVENESS PUBLIC ADVISORY COUNCIL (NEW ENGLAND CEPAC), A CORE PROGRAM OF THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER), IS A NATIONALLY-RECOGNIZED COMMUNITY FORUM. THE NEW ENGLAND CEPAC CONVENES THREE TIMES EACH YEAR AT PUBLIC MEETINGS TO REVIEW OBJECTIVE EVIDENCE REPORTS AND DEVELOP RECOMMENDATIONS FOR HOW STAKEHOLDERS CAN APPLY EVIDENCE TO IMPROVE THE QUALITY AND VALUE OF HEALTH CARE.NEW ENGLAND CEPAC DIRECTLY ENGAGES CLINICIANS, PATIENTS, AND PAYERS DURING PUBLIC MEETINGS TO DISCUSS IMPLICATIONS OF THE EVIDENCE FOR CLINICAL DECISION-MAKING AND COVERAGE POLICIES. APPLICATION OF EVIDENCE TAKES SHAPE THROUGH NEW MEDICAL POLICIES, BENEFIT DESIGNS, AND PATIENT AND CLINICIAN TOOLS TO IMPROVE CLINICAL CARE AND PATIENT OUTCOMES. 721474 NEW DRUG ASSESSMENT PROGRAM: ICER'S PROGRAM TO EVALUATE NEW DRUGS AT OR NEAR THE TIME OF FDA APPROVAL PROVIDES AN INDEPENDENT ANALYSIS OF THE COMPARATIVE EFFECTIVENESS OF NEW DRUGS, ALONG WITH AN ASSOCIATED "VALUE-BASED" PRICE BENCHMARK, WITH THE OBJECTIVE OF HELPING DECISION-MAKERS UNDERSTAND AND APPLY EVIDENCE TO IMPROVE VALUE THROUGHOUT THE HEALTH CARE SYSTEM. THE REPORTS OF THE NEW DRUG ASSESSMENT PROGRAM ARE VETTED THROUGH A PUBLIC PROCESS. 132374 PROVEN BEST CHOICES: IS AN INITIATIVE TO DEVELOP AND DISSEMINATE A SERIES OF GUIDES TO AID PATIENTS AND CLINICIANS IN MAKING HIGH-VALUE HEALTH CARE CHOICES. THE GUIDES, DEVELOPED BY ICER IN PARTNERSHIP WITH FAMILIES USA, TRANSLATE INFORMATION FROM ICER'S EVIDENCE REVIEWS INTO A PATIENT-FRIENDLY FORMAT. RECEIVING THE PROVEN BEST CHOICES RATING IS DEPENDENT ON TWO KEY FACTORS: HOW WELL ONE OPTION WORKS COMPARED TO OTHERS BASED ON SCIENTIFIC EVIDENCE, AND HOW MUCH ONE CHOICE COSTS IN RELATION TO ITS LONG-TERM BENEFITS. OPTIONS RECEIVING THIS RATING ARE HIGH VALUE CHOICES-THOSE THAT ARE PROVEN TO WORK WELL AND OFFER REASONABLE BENEFITS IN RELATION TO THEIR COSTS. THESE GUIDES ARE INTENDED TO HELP PATIENTS PREPARE FOR AND ENGAGE IN MEANINGFUL DISCUSSIONS WITH THEIR DOCTORS ABOUT THE CHOICES AVAILABLE TO THEM. 569707 1012499 MEMBERSHIP: THE ICER MEMBERSHIP PROGRAM LAUNCHED IN 2015 TO GIVE A SELECT NUMBER OF LEADING HEALTH CARE ORGANIZATIONS A UNIQUE OPPORTUNITY TO SHAPE THE FUTURE OF EVIDENCE AND COVERAGE POLICY IN THE U.S. THE TENSION BETWEEN INNOVATION AND HEALTH CARE COSTS CONTINUES TO FOCUS CRITICAL ATTENTION ON HOW EVIDENCE WILL BE DEVELOPED BY MANUFACTURERS AND HOW IT WILL BE INTERPRETED BY PAYERS IN MAKING COVERAGE DECISIONS. BENEFITING FROM ICER'S EXPERIENCE AS A LEADER IN HEALTH TECHNOLOGY ASSESSMENT, AND ITS UNIQUE ABILITY TO SERVE AS AN ENGAGED, OBJECTIVE CONVENER AND MODERATOR, ICER MEMBERSHIP BRINGS TOGETHER A SMALL, INFLUENTIAL GROUP OF EVIDENCE LEADERS FROM INSURERS, PHARMACY BENEFIT MANAGEMENT FIRMS, HEALTH TECHNOLOGY ASSESSMENT GROUPS, AND LIFE SCIENCE COMPANIES TO ADDRESS KEY CONTROVERSIES IN EVIDENCE METHODS AND POLICY. WORKING TOGETHER IN A BALANCED, NON-ADVERSARIAL ENVIRONMENT, ICER MEMBERS GAIN THE SKILLS AND INSIGHTS IN EVIDENCE POLICY NECESSARY TO STRENGTHEN THEIR COMPETITIVE POSITION IN THE MARKETPLACE. 53626 85473 WASHINGTON STATE HEALTH CARE AUTHORITY: IN 2012, ICER WAS NAMED ONE OF WASHINGTON STATE HEALTH CARE AUTHORITY'S HEALTH TECHNOLOGY ASSESSMENT PROGRAM'S THREE TECHNOLOGY ASSESSMENT CENTERS AND COMPLETES ONE TO THREE COMPARATIVE EFFECTIVENESS ASSESSMENTS A YEAR FOR THE AGENCY. THE MISSION OF THE WASHINGTON STATE HEALTH CARE AUTHORITY'S HEALTH TECHNOLOGY ASSESSMENT PROGRAM IS TO ENSURE THAT MEDICAL TREATMENTS AND SERVICES PAID FOR WITH STATE HEALTH CARE DOLLARS ARE SAFE AND PROVEN TO WORK. THE PROGRAM CONTRACTS FOR SCIENTIFIC, EVIDENCE-BASED REPORTS ABOUT WHETHER CERTAIN MEDICAL DEVICES, PROCEDURES, AND TESTS ARE SAFE AND WORK AS PROMOTED, AND AN INDEPENDENT CLINICAL COMMITTEE OF HEALTH CARE PRACTITIONERS THEN USES THE REPORTS TO DETERMINE IF PROGRAMS SHOULD PAY FOR THE MEDICAL DEVICE, PROCEDURE, OR TEST. THE CLINICAL COMMITTEE HAS A LEGISLATIVE MANDATE TO CONSIDER, IN AN OPEN AND TRANSPARENT PROCESS, EVIDENCE REGARDING THE SAFETY, EFFICACY, AND COST-EFFECTIVENESS OF THE TECHNOLOGY BEING REVIEWED. 554513 THE MIDWEST COMPARATIVE EFFECTIVENESS PUBLIC ADVISORY COUNCIL (MIDWEST CEPAC), A CORE PROGRAM OF THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER), IS A NATIONALLY-RECOGNIZED COMMUNITY FORUM. THE MIDWEST CEPAC CONVENES THREE TIMES EACH YEAR AT PUBLIC MEETINGS TO REVIEW OBJECTIVE EVIDENCE REPORTS AND DEVELOP RECOMMENDATIONS FOR HOW STAKEHOLDERS CAN APPLY EVIDENCE TO IMPROVE THE QUALITY AND VALUE OF HEALTH CARE.MIDWEST CEPAC DIRECTLY ENGAGES CLINICIANS, PATIENTS, AND PAYERS DURING PUBLIC MEETINGS TO DISCUSS IMPLICATIONS OF THE EVIDENCE FOR CLINICAL DECISION-MAKING AND COVERAGE POLICIES. APPLICATION OF EVIDENCE TAKES SHAPE THROUGH NEW MEDICAL POLICIES, BENEFIT DESIGNS, AND PATIENT AND CLINICIAN TOOLS TO IMPROVE CLINICAL CARE AND PATIENT OUTCOMES. 22500 OTHER ACTIVITIES INCLUDING SPEAKING FEES AND SMALL POLICY PROJECTS. 1310220 1120472 4216574 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 61 0 1 24 1 0 0 0 0 0 0 0 0 0 0 X 10 10 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA MA X THE ORGANIZATION 6175284013 TWO LIBERTY SQUARE NINTH FLOOR BOSTON MA 02109 PETER LONG PHD DIRECTOR 1.00 X 0 0 0 MARCUS THYGESON MD MPH DIRECTOR 1.00 X 0 0 0 LEWIS SANDY MD DIRECTOR 1.00 X 0 0 0 CARMELLA BOCCHINO RN MBA DIRECTOR 1.00 X 0 0 0 WENDY EVERETT SCD DIRECTOR 1.00 X 0 0 0 RON POLLACK JD DIRECTOR 1.00 X 0 0 0 DEBORAH FREUND PHD DIRECTOR 1.00 X 0 0 0 FRANCES VISCO DIRECTOR (SINCE OCTOBER 2016) 1.00 X 0 0 0 ELLEN ANDREWS DIRECTOR (SINCE OCTOBER 2016) 1.00 X 0 0 0 MURRAY ROSS PHD CHAIR 1.00 X X 0 0 0 STEVEN D PEARSON PRESIDENT 50.00 X 519918 0 40565 SARAH K EMOND TREASURER, SECRETARY, COO 50.00 X 171315 0 23426 DAN OLLENDORF CHIEF SCIENTIFIC OFFICER 50.00 X 218875 0 39276 RICHARD CHAPMAN DIRECTOR OF HEALTH ECONOMICS 50.00 X 194037 0 8276 DAVID RIND CHIEF MEDICAL OFFICER 50.00 X 141733 0 16867 WILLIAM DREITLEIN DIRECTOR OF PHARMACEUTICAL POLICY 50.00 X 130166 0 21086 MITCHELL STEIN POLICY & COMMUNICATIONS DIRECTOR 50.00 X 123031 0 13478 SONYA KHAN PROGRAM DIRECTOR 50.00 X 108981 0 12921 1608056 0 175895 8 0 1 0 UNIVERSITY OF WASHINGTON 1410 NE CAMPUS PARKWAY SEATTLE WA 98195 RESEARCH 228816 REGENTS OF THE U OF CA 1111 FRANKLIN ST 12TH FL OAKLAND CA 94607 RESEARCH 150000 MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT ST BOSTON MA 02114 RESEARCH 119090 3 286234 286234 MEMBERSHIP DUES 900099 1012499 1012499 CONTRACT SERVICE REVEN 541700 107973 107973 1120472 1381 1381 1408087 1120472 0 1381 X 974795 925222 31007 18566 1329473 1329473 43141 43141 117419 117419 130738 128306 1844 588 13796 399 13397 65737 65737 1000185 991582 8486 117 34599 34164 376 59 90323 90094 187 42 236108 232701 3123 284 116771 97652 19119 217931 182249 35682 90885 1292 89593 14541 3181 11360 PROFESSIONAL DEVELOPMEN 81619 39699 41920 4558061 4216574 321831 19656 462145 324284 2352114 2469313 3354270 165673 239347 210500 53687 40190 524172 73118 84928 451054 192895 201802 6739386 3862816 360053 208555 557500 625003 0 357399 917553 1190957 X 1030076 1282272 4791757 1389587 5821833 2671859 6739386 3862816 -3149974 0 X X 0 1 X 1 0 X 437827 2037603 5481696 286234 8243360 437827 2037603 5481696 286234 8243360 6251840 1991520 121 1381 1502 8244862 2475947 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 428529 49642 378887 95643 23476 72167 451054 SECURITY DEPOSITS 136890 WEBSITE DEVELOPMENT COSTS 64912 201802 DEFERRED RENT 357399 357399 X 1408087 0 1408087 0 1408087 4558061 0 4558061 0 4558061 PART X, LINE 2: THE ORGANIZATION IS A NONPROFIT CORPORATION AS DESCRIBED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES ON TRADE OR BUSINESS PROFITS GENERATED BY ACTIVITIES RELATED TO THE ORGANIZATION'S EXEMPT FUNCTION. THE ORGANIZATION MAY BE SUBJECT TO FEDERAL AND STATE INCOME TAXES FOR PROFITS GENERATED FROM TRADE OR BUSINESS ACTIVITIES UNRELATED TO THE ORGANIZATION'S EXEMPT FUNCTION. AS OF DECEMBER 31, 2016, MANAGEMENT BELIEVES THAT THE ORGANIZATION HAS NOT GENERATED ANY UNRELATED BUSINESS TAXABLE INCOME. THE ORGANIZATION ASSESSES THE RECORDING OF UNCERTAIN TAX POSITIONS BY EVALUATING THE MINIMUM RECOGNITION THRESHOLD AND MEASUREMENT REQUIREMENTS A TAX POSITION MUST MEET BEFORE BEING RECOGNIZED AS A BENEFIT IN THE FINANCIAL STATEMENTS. X X X X 0 0 0 0 0 0 0 0 0 STEVEN D PEARSON PRESIDENT 444918 0 75000 0 0 0 23850 0 16715 0 560483 0 0 0 SARAH K EMOND TREASURER, SECRETARY, COO 168815 0 2500 0 0 0 14700 0 8726 0 194741 0 0 0 DAN OLLENDORF CHIEF SCIENTIFIC OFFICER 216375 0 2500 0 0 0 20055 0 19221 0 258151 0 0 0 RICHARD CHAPMAN DIRECTOR OF HEALTH ECONOMICS 191537 0 2500 0 0 0 5832 0 2444 0 202313 0 0 0 DAVID RIND CHIEF MEDICAL OFFICER 141733 0 0 0 0 0 4113 0 12754 0 158600 0 0 0 WILLIAM DREITLEIN DIRECTOR OF PHARMACEUTICAL POLICY 127666 0 2500 0 0 0 3862 0 17224 0 151252 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS FIRST REVIEWED IN DETAIL BY THE ORGANIZATION'S SENIOR MANAGEMENT TEAM. A FULL COPY OF THE FORM 990 IS THEN PROVIDED TO THE ENTIRE BOARD OF DIRECTORS FOR REVIEW PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S CODE OF BUSINESS CONDUCT AND ETHICS, WHICH INCLUDES A CONFLICT OF INTEREST POLICY, IS REVIEWED ON AN ANNUAL BASIS. ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE REQUIRED TO COMPLETE AND SIGN THE CONFLICT OF INTEREST POLICY ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION FOR THE OFFICERS OF THE ORGANIZATION IS REVIEWED AND APPROVED BY THE GOVERNING BOARD'S COMPENSATION COMMITTEE ON AN ANNUAL BASIS.IN DOING SO, THE COMPENSATION COMMITTEE REVIEWS COMPENSATION DATA FROM PEER ORGANIZATIONS. COMPENSATION OF ADDITIONAL KEY EMPLOYEES IS REVIEWED AND APPROVED BY THE OFFICERS OF THE ORGANIZATION. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CODE OF BUSINESS CONDUCT AND ETHICS, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G MARKETING AND COMMUNICATIONS: PROGRAM SERVICE EXPENSES 78,167. MANAGEMENT AND GENERAL EXPENSES 1,392. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 79,559. OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 33,744. MANAGEMENT AND GENERAL EXPENSES 519. FUNDRAISING EXPENSES 117. TOTAL EXPENSES 34,380. CONTRACTOR SERVICES: PROGRAM SERVICE EXPENSES 879,671. MANAGEMENT AND GENERAL EXPENSES 6,575. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 886,246. FORM 990, PART XII, LINE 2C: THE ORGANIZATION HAS A COMMITTEE THAT ASSUMES RESPONSIBILITY FOR OVERSIGHT FOR THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THIS PROCESS HAS NOT CHANGED DURING THE YEAR.